NCT05142189: Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
- State
- Under way
- Phase
- Phase 1
- People
- 320 planned
- Started
- 17 Jun 2022
- Primary completion
- Feb 2030
- Arms
- Cohort 2 - BNT116 + Cemiplimab (PD-1/PD-L1 Inhibitor Refractory/Relapsed Participants), Cohort 4 - BNT116 + Cemiplimab (Frail Participants), Cohort 5 - BNT116 + Cemiplimab (After Concurrent Chemoradiotherapy [CRT])
- Results
- None posted
- 2 Dec 2021: Trial registered
- 17 Jun 2022: Trial started